Revenue Summary of BiomX Inc.

BiomX Inc.'s latest annual revenue in 2023 was -357 Thousand USD , down -166.42% from previous year.
BiomX Inc.'s latest quarterly revenue in 2024 Q2 was -2.01 Million USD , up 100.0% from previous quarter.
BiomX Inc. reported a annual revenue of -134 Thousand USD in annual revenue 2022, down 0.0% from previous year.
BiomX Inc. reported a annual revenue of - USD in annual revenue 2021, down 0.0% from previous year.
BiomX Inc. reported a quarterly revenue of -2.01 Million USD for 2024 Q2, up 100.0% from previous quarter.
BiomX Inc. reported a quarterly revenue of -87 Thousand USD for 2023 Q4, up 2.25% from previous quarter.

Annual Revenue Chart of BiomX Inc. (2023 - 2017)

Name	Revenue	Revenue Difference
AIM ImmunoTech Inc.	202 Thousand USD	276.733%
Ampio Pharmaceuticals, Inc.	- USD	Infinity%
Armata Pharmaceuticals, Inc.	4.52 Million USD	107.883%
Actinium Pharmaceuticals, Inc.	81 Thousand USD	540.741%
Azitra, Inc.	686 Thousand USD	152.041%
Can-Fite BioPharma Ltd.	743 Thousand USD	148.048%
Chromocell Therapeutics Corporation	- USD	Infinity%
Calidi Biotherapeutics, Inc.	- USD	Infinity%
CEL-SCI Corporation	- USD	Infinity%
iBio, Inc.	225 Thousand USD	258.667%
Lineage Cell Therapeutics, Inc.	8.94 Million USD	103.991%
MAIA Biotechnology, Inc.	- USD	Infinity%
Matinas BioPharma Holdings, Inc.	1.09 Million USD	132.573%
Navidea Biopharmaceuticals, Inc.	65.65 Thousand USD	643.776%
NovaBay Pharmaceuticals, Inc.	14.72 Million USD	102.424%
NanoViricides, Inc.	- USD	Infinity%
Oragenics, Inc.	37.65 Thousand USD	1048.132%
BiomX Inc.	-357 Thousand USD	-0.0%
Protalix BioTherapeutics, Inc.	65.49 Million USD	100.545%
Palatin Technologies, Inc.	4.49 Million USD	107.951%
Scorpius Holdings, Inc.	6.99 Million USD	105.104%